<?xml version="1.0" encoding="UTF-8"?>
<p>It was previously shown for a closely-related alphavirus, CHIKV, that inhibition of CD4+ T cell infiltration with an FDA-approved drug could reduce disease phenotype in the virus-infected joint (
 <xref rid="B28" ref-type="bibr">28</xref>). Therefore, we assessed if a similar treatment strategy would be beneficial against CD4+ T cell-induced pathology during ONNV infection. ONNV-infected mice were subjected to a post-infection treatment regimen of fingolimod (FTY720, 20 Î¼g daily from 2 to 6 dpi). Treatment successfully abrogated joint swelling, with no effect on viremia (
 <xref ref-type="fig" rid="F5">Figures 5A,B</xref>).
</p>
